Yost, Kathleen J.

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.

Webster, K., Cella, D. F., & Yost, K. J. (2003) · Health and Quality of Life Outcomes

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 1,506

Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 919

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients

Yost, K. J., Eton, D. T., Garcia, S. F., & Cella, D. (2011) · Journal of Clinical Epidemiology

Cancer survivorship and carePsychometric Methodologies and Testing

Cited by 597

General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G)

Brucker, P. S., Yost, K., Cashy, J., Webster, K., & Cella, D. (2005) · Evaluation & the Health Professions

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 528

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., Sledge, G. W., & Wood, W. C. (2004) · Journal of Clinical Epidemiology

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 390

Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences: The FACIT Experience

Yost, K. J., & Eton, D. T. (2005) · Evaluation & the Health Professions

Health Systems, Economic Evaluations, Quality of LifeCancer survivorship and care

Cited by 382

Norming plans for the NIH Toolbox

Beaumont, J. L., Havlik, R., Cook, K. F., Hays, R. D., Wallner-Allen, K., Korper, S. P., Lai, J.-S., Nord, C., Zill, N., Choi, S., et al. (2013) · Neurology

Psychometric Methodologies and TestingPsychological Testing and Assessment

Cited by 106

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 95

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology

Pancreatic and Hepatic Oncology ResearchAdvanced Breast Cancer Therapies

Cited by 94

Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial

Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 80

Dermatopathologists' concerns and challenges with clinical information in the skin biopsy requisition form: a mixed‐methods study

Comfere, N. I., Peters, M. S., Jenkins, S., Lackore, K., Yost, K., & Tilburt, J. (2015) · Journal of Cutaneous Pathology

Clinical Laboratory Practices and Quality ControlHealthcare Systems and Technology

Cited by 40